TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06024733
Drug: Target Controlled Infusion and lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive total intravenous anesthesia with propofol Target Controlled Infusion. At the induction of anesthesia, the patients will receive a bolus of lidocaine 1% 1.5 mg/kg and a continuous infusion of lidocaine 1% 2 mg/kg/h will be associated throughout the procedure.
Study: NCT06274905
Drug: EMLA
Normalized name: EMLA
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream
Study: NCT06274905
Drug: Ethyl chloride
Normalized name: Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl chloride
Study: NCT05862285
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Study: NCT05862285
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab in combination with atezolizumab will be administered at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Study: NCT05862285
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered as a monotherapy and in combination with tiragolumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Study: NCT06306443
Drug: extended-release buprenorphine (XR-B)
Normalized name: Buprenorphine Extended-Release Injection
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: buprenorphine
Study: NCT05155709
Drug: siremadlin
Normalized name: Siremadlin
DrugBank: Siremadlin (DB16331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siremadlin is a capsule taken orally once a day (QD) and comes in 10 mg, 20 mg and 30 mg strengths
Study: NCT05155709
Drug: venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax is a tablet taken orally once a day (QD) and comes in 10 mg, 50 mg and 100 mg strengths.
Study: NCT05155709
Drug: azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine is a powder for suspension for injection or powder for solution for infusion taken intravenously or subcutaneously according to standard local clinical practice
Study: NCT06385990
Drug: UTD1
Normalized name: Uridine Triacetate
DrugBank: Uridine triacetate (DB09144)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UTD1: 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles.
Study: NCT04830644
Drug: Iguratimod
Normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Iguratimod orally twice a day
Study: NCT04968054
Drug: Arm I (Propofol)
Normalized name: IOBENGUANE I 123
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively.
Study: NCT05856227
Drug: Ceftobiprole medocaril
Normalized name: Ceftobiprole medocaril
DrugBank: Ceftobiprole medocaril (DB14733)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftobiprole medocaril: 7.5 mg/kg every 12 hours to 15 mg/kg every 8 hours, administered IV as a 2-hour infusion.
Study: NCT04968054
Drug: Arm II (Remimazolam)
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam group started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
Study: NCT04768985
Drug: Treatment A: Acalabrutinib tablet
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive fixed single doses of acalabrutinib tablet in 2 treatment periods, under fasted conditions.
Study: NCT04768985
Drug: Treatment B: Acalabrutinib capsule
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive fixed single doses of acalabrutinib capsule in 2 treatment periods, under fasted conditions.
Study: NCT05868720
Drug: Risperidone, Aripiprazole
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patients who are randomized to Risperidone group will receive Risperidone at a dose of 1mg/day during the study period that is for 6 weeks. The patients who are randomized to Aripiprazole group will receive Aripiprazole at a dose of 2mg/day during the study period that is for 6 weeks.
Study: NCT06066580
Drug: Sevasemten
Normalized name: Sevasemten
DrugBank: Sevasemten (DB18983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevasemten is administered orally once per day
Study: NCT06181682
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal Dexmedetomidine
Study: NCT06181682
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam
Study: NCT06781385
Drug: Intra-arterial Tenecteplase
Normalized name: methotrexate
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-time dose of intra-arterial tenecteplase post-thrombectomy
Study: NCT06772480
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive oral thalidomide starting at 50 mg daily, with a weekly increase of 50 mg up to a maximum of 200 mg daily, continued for four months
Study: NCT00001115
Drug: Acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000626
Drug: Vinblastine sulfate
Normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000626
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000626
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000626
Drug: Bleomycin sulfate
Normalized name: Bleomycin Sulfate
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05913310
Drug: Kui-Yuan Chewable Tablets
Normalized name: NAPHAZOLINE HYDROCHLORIDE 1 mg NASAL SOLUTION/ DROPS [Pi Yuan Chin]
DrugBank: Naphazoline (DB06711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kui-Yuan chewable tablets are the optimal ingredients found in sunflower dish that can reduce uric acid and anti-gout, including flavonoids, Coumarin (including scopolamine) and phenolic acids.
Study: NCT05702073
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
Study: NCT05913310
Drug: Placedo of Kui-Yuan Chewable Tablets
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placedo of Kui-Yuan Chewable Tablets are composed of L-arabinose, food starch and a few auxiliary materials.
Study: NCT05106504
Drug: Medical Cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be assessed before and after use of Medical cannabis via inhaled dried buds or sublingual oil extract
Study: NCT04741698
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol 2mg IV
Study: NCT06610682
Drug: Plixorafenib
Normalized name: Lifirafenib
DrugBank: Lifirafenib (DB14773)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plixorafenib (900mg) daily co-administered with cobicistat (150mg daily) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth under fasting conditions continuously for 28-day cycles until progressive disease or up to 24 cycles
Study: NCT06610682
Drug: Cobicistat 150 MG [Tybost]
Normalized name: cobicistat 150 MG [Tybost]
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Plixorafenib (900mg) daily co-administered with cobicistat (150mg daily) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth under fasting conditions continuously for 28-day cycles until progressive disease or up to 24 cycles
Study: NCT05794243
Drug: Sodium Caprate (C10)
Normalized name: octyl caprate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04668222
Drug: Liu-Wei-Di-Huang formula
Normalized name: di-isopropylammonium
DrugBank: Propyl acetate (DB01670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liu-Wei-Di-Huang formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08273). The intake dosage is 5g twice daily.
Study: NCT06440980
Drug: Orforglipron
Normalized name: Orforglipron
DrugBank: Orforglipron (DB18964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05057247
Drug: Duvelisib
Normalized name: Duvelisib
DrugBank: Duvelisib (DB11952)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Duvelisib capsules should be swallowed whole with a glass of water (approximately 8 ounces).~Advise patients not to open, break, or chew the capsules. Duvelisib may be administered without regard to meals; however, subjects should avoid grapefruit and grapefruit juice while on duvelisib.~continue for up to 24 months.
Study: NCT05057247
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel chemotherapy once every 21 days (by intravenous infusion) over about 30- 60 minutes at each visit. This will continue for up to 24 months
Study: NCT05703919
Drug: Titrated Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titrated oxygen strategy - a mix of supplemental oxygen and compressed atmospheric air as driver for inhaled bronchodilators to target SpO2 88-92%
Study: NCT05703919
Drug: Standard Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard care using compressed oxygen (100%) as driver for inhaled bronchodilators
Study: NCT04766476
Drug: BMS-963272
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT05274802
Drug: ALS-4
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ALS-4 before Breakfast
Study: NCT05274802
Drug: ALS-4
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose three separate times in crossover fashion: (1) fasted morning dose; (2) fed morning dose; (3) fasted evening dose
Study: NCT05274802
Drug: ALS-4
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of ALS-4 up to two times daily
Study: NCT06439225
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m2 q21 days
Study: NCT06439225
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC5 q21 days
Study: NCT05658562
Drug: MT-2111
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion
Study: NCT05518123
Drug: Rimegepant
Normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rimegepant 75 mg Oral Disintegrating Tablet (ODT) taken every other day during Double-blind Treatment (DBT) phase
Study: NCT04843982
Drug: Esketamine hydrochloride
Normalized name: esketamine hydrochloride
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days.
Study: NCT06800248
Drug: emodepside (BAY 44-4400)
Normalized name: Emodepside
DrugBank: Emodepside (DB11403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with single dose of oral 15 mg emodepside
Study: NCT06800248
Drug: Mebendazole 100 MG
Normalized name: mebendazole 100 MG
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with 100 mg mebendazole orally administered b.i.d. for 3 days
Study: NCT06800248
Drug: similar placebo to mebendazole
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with mebendazole similar placebo orally administered b.i.d. for 3 days
Study: NCT06800248
Drug: matching placebo of emodepside
Normalized name: Emodepside
DrugBank: Emodepside (DB11403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with single dose of oral emodepside matching placebo
Study: NCT06397027
Drug: Ziftomenib
Normalized name: Ziftomenib
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV
Study: NCT06397027
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by PO
Study: NCT06397027
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by PO
Study: NCT06444113
Drug: Ofatunumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No study-treatment is provided for this study. Study participants will be treated with commercially available ofatumumab according to the local label.
Study: NCT06760403
Drug: Hypochlorous acid
Normalized name: Hypochlorous acid
DrugBank: Hypochlorous acid (DB14135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypochlorous acid, chlorhexidine and saline groups were compared as postoperative gargles after gingivectomy surgery.
Study: NCT06015308
Drug: Amlitelimab
Normalized name: Amlitelimab
DrugBank: Amlitelimab (DB18835)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection in abdomen, outer thigh, or upper arm
Study: NCT05109052
Drug: PXS-5505 and Atezolizumab and Bevacizumab
Normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Open label safety and tolerability assessment of PXS-5505 incorporating first-line combination therapy Atezolizumab and Bevacizumab
Study: NCT04689815
Drug: Oral Arsenic Trioxide Formulation
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eligible subjects with NPM1 MRD positivity will receive oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle). Each cycle of oral-As2O3 plus azacitidine will be given once every 28 days. The total duration of treatment is 12 months (12 cycles). Treatment will be day-care and outpatient based. Reduction in the dosage and duration of oral-As2O3 is required if the subject is experiencing adverse events (AEs). In case of grade 3 or above toxicity, the dosage of oral-As2O3 will be reduced to 5mg per day.
Study: NCT05024734
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In PDOs from patients that show highest response to Epirubicin, this drug will be instilled intravesically once weekly for 6 times.~Epirubicin is also the default drug, in case of failure of drug prediction in the in-vitro drug screen in PDO.~Epirubicin will be used as a concentrate for injection/instillation 2 mg/ml in total 50mg per vial. Prior to use, the concentrate for injection is diluted with 25ml of 0.9% saline solution to obtain the final Solution with 1mg/ml of Epirubicin.
Study: NCT05024734
Drug: Mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In PDOs from patients that show highest response to Mitomycin, this drug will be instilled intravesically once weekly for 6 times.~Mitomycin C will be used as 20mg dry powder. Prior to use, the powder will be dissolved in 50ml of 0.9% saline solution according to the manufacturer instructions
Study: NCT05024734
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In PDOs from patients that show highest response to Gemcitabine, this drug will be instilled intravesically once weekly for 6 times.~Gemcitabine will be used as 2000 mg/50ml. For intravesical application, 1000mg of gemcitabine (corresponding to 25ml) will be diluted in 25ml 0.9% saline solution, to obtain the gemcitabine concentration of 1000mg/50ml used for instillation.
Study: NCT05024734
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In PDOs from patients that show highest response to Docetaxel, this drug will be instilled intravesically once weekly for 6 times.~Docetaxel will be used as 140mg/7ml solution. For intravesical application, 48.825ml of saline will be added to 1.875ml Docetaxel solution (according 37.5mg of Docetaxel). The concentration of this solution is 0.74mg/ml by a total volume of the instillation solution of 50,7.
Study: NCT05965440
Drug: impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients
Normalized name: Gel-One
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Analysis of microbiota
Study: NCT06132503
Drug: LP-284
Normalized name: LP-284
DrugBank: LP-284 (DB18006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LP-284 is a small molecule alkylating agent causing tumor cell death through DNA damage.
Study: NCT05559879
Drug: Cabo + Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Combination of standard dose of cabozantinib and 500 mg dostarlimab for first 4 cycles followed by standard dose of cabozantinib and 1000 mg of dostarlimab until 2 years of treatment
Study: NCT05086939
Drug: Autologous MSCs
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection 40 million/4 ml.
Study: NCT05086939
Drug: Allogenic MSCs
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection 40 million/4 ml.
Study: NCT05086939
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-articular injection 60mg / 3 ml .
Study: NCT05035576
Drug: OPN-019
Normalized name: anti-Tlr2 monoclonal antibody OPN-305
DrugBank: Tomaralimab (DB15415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg OPN-019, 2 sprays per nostril (one dose)
Study: NCT05058417
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: participants will receive 10 mg Empagliflozin for 8 consecutive weeks in addition to the standard therapy
Study: NCT05853627
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol will be administered 60-min prior to each of six weekly 10-20 min. traumatic memory reactivation sessions.
Study: NCT04590664
Drug: Verteporfin
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT05309928
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: medication administration
Study: NCT05379829
Drug: Ziltivekimab
Normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered 3 doses subcutaneously (s.c.) every four weeks (Q4W).
Study: NCT06218069
Drug: Sasanlimab
Normalized name: Sasanlimab
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL of the study drug will be administered subcutaneous injection in the abdominal fat fold. If SC injections in the abdominal location are not possible, SC injections can be administered in a distributed manner in the thighs. SC injections in the upper extremities (eg, deltoid, upper and lower arm) are not permitted. Any observed abnormality at the injection site (e.g. erythema, induration, ecchymosis, injection site pain, injection site pruritus) will be monitored and judged by the investigator to determine whether a corresponding AE should be reported.
Study: NCT06218069
Drug: [89Zr]Zr-crefmirlimab berdoxam
DrugBank: Crefmirlimab (DB17577)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to sasanlimab injection and prior to surgery, \[89Zr\]Zr-crefmirlimab berdoxam (1.5 mg protein dose labelled with activity dose 37 MBq Zirconium-89) will be administered via an intravenous catheter. After 21-27 hours after injection patient will undergo a whole-body PETscan te detect CD8+ T-cell infiltration.
Study: NCT06279910
Drug: Calcifediol
Normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcifediol added as a treatment to the rest of the prescribed drugs of the protocol
Study: NCT04656275
Drug: BI 1323495
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1323495
Study: NCT04991324
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24,000 IU cholecalciferol
Study: NCT04713202
Drug: Telotristat ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telotristat Ethyl, 250mg
Study: NCT04713202
Drug: Peptide Receptor Radionuclide Therapy
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide Receptor Radionuclide Therapy
Study: NCT04687631
Drug: mFOLFOXIRI plus Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: cetuximab 500mg/m2 + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks